Pramipexole and Rasagiline Mesylate Sustained-release Capsules(Zhejiang Jingxin Pharma)

普拉克索雷沙吉兰缓释胶囊（浙江京新药业）

Report date: 2025/08/29 16:20:38

Base Information

Drug NamePramipexole and Rasagiline Mesylate Sustained-release Capsules(Zhejiang Jingxin Pharma)
Drug Alias NameRasagaline/pramipexole盐酸普拉克索/甲磺酸雷沙吉兰Rasagiline Mesylate/Pramipexole Dihydrochloride Hydrate普拉克索雷沙吉兰缓释胶囊（2.2类改良型）Pramipexole/Rasagiline +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D3 receptor agonistsMonoamine oxidase B inhibitorsDopamine D2 receptor agonists +[4] 
TargetsMonoamine oxidase BDopamine D2 receptorDopamine D4 receptor +[4] 
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang Jingxin Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Jingxin Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A